Abstract
Summary
The North America acute respiratory distress syndrome (ARDS) treatment market is expected to reach USD 4,096,703.49 thousand by 2030, from USD 1,807,544.80 thousand in 2022, growing at the CAGR of 11.2% in the forecast period of 2023 to 2030.
Market Segmentation
North America Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country ( U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030
Overview of North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics
Driver
• Increasing prevalence and incidence of acute lung injury in the market
Restraint
• High cost of device and treatment
Opportunity
• Strategic initiatives joined with new product launches by market players
Market Players
Some of the major market players operating in the North America Acute Respiratory Distress Syndrome (ARDS) treatment market are listed below:
• Gilead Sciences, Inc.
• Terumo Medical Corporation
• Getinge .
• LivaNova PLC
• Medtronic
• ResMed
• Fisher & Paykel Healthcare Limited.
• Drägerwerk AG & Co. KGaA
• NIPRO
• Fresenius SE & Co. KGaA
• Hamilton Medical
• Pfizer Inc.
• WEINMANN Emergency Medical Technology GmbH + Co. KG
• EUROSETS
• Armstrong Medical
• nice Neotech Medical Systems Pvt. Ltd.
• Besmed Health Business Corp.
Table of Contents
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 16
1.4 LIMITATIONS 18
1.5 MARKETS COVERED 18
2 MARKET SEGMENTATION 20
2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 CURRENCY AND PRICING 22
2.5 DBMR TRIPOD DATA VALIDATION MODEL 23
2.6 MULTIVARIATE MODELLING 26
2.7 TYPE LIFELINE CURVE 26
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.9 DBMR MARKET POSITION GRID 28
2.10 MARKET END USER COVERAGE GRID 29
2.11 VENDOR SHARE ANALYSIS 30
2.12 SECONDARY SOURCES 31
2.13 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 35
4.1 PESTEL ANALYSIS 36
4.2 PORTER’S FIVE FORCES 37
4.3 INSURANCE REIMBURSEMENT 38
4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 38
4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 38
4.3.3 ABBOTT CODING GUIDE FOR ECMO 39
4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 39
4.3.5 CERN HEALTH INSURANCE SCHEME 40
4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 40
4.3.7 AMERICAN HOSPITAL ASSOCIATION 41
4.4 PIPELINE ANALYSIS 42
4.5 PRICING ANALYSIS 44
5 MARKET OVERVIEW 45
5.1 DRIVERS 47
5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 47
5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 47
5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 48
5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 48
5.2 RESTRAINTS 49
5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 49
5.2.2 HIGH COST OF DEVICES AND TREATMENT 49
5.3 OPPORTUNITIES 50
5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 50
5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 50
5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 51
5.4 CHALLENGES 52
5.4.1 STRINGENT RULES & REGULATIONS 52
5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 53
6 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 54
6.1 OVERVIEW 55
6.2 MECHANICAL VENTILATION 58
6.2.1 HIGH-FLOW NASAL O2 59
6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 59
6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 59
6.2.4 PRONE POSITION VENTILATION 59
6.2.5 OTHERS 60
6.3 CORTICOSTEROIDS 60
6.3.1 METHYLPREDNISOLONE 61
6.3.2 DEXAMETHASONE 61
6.3.3 OTHERS 61
6.4 ANTIVIRAL MEDICATION 62
6.4.1 RIBAVIRIN 63
6.4.2 OSELTAMIVIR 63
6.4.3 OTHERS 63
6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 63
6.6 TOCILIZUMAB 64
6.7 OTHERS 64
7 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 65
7.1 OVERVIEW 66
7.2 SEPSIS 69
7.3 INHALATION OF HARMFUL SUBSTANCES 69
7.4 SEVERE PNEUMONIA 70
7.5 OTHERS 70
8 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 71
8.1 OVERVIEW 72
8.2 PARENTERAL 75
8.2.1 INTRAVENOUS 75
8.2.2 INTRAMUSCULAR 75
8.3 ORAL 76
8.4 OTHERS 76
9 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 77
9.1 OVERVIEW 78
9.2 HOSPITALS 81
9.3 SPECIALTY CLINICS 81
9.4 HOME HEALTHCARE 82
9.5 OTHERS 82
10 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 83
10.1 OVERVIEW 84
10.2 DIRECT TENDER 87
10.3 HOSPITAL PHARMACY 87
10.4 RETAIL PHARMACY 88
10.5 ONLINE PHARMACY 88
11 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 89
11.1 NORTH AMERICA 91
11.1.1 U.S 96
11.1.2 CANADA 101
11.1.3 MEXICO 106
12 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 111
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 111
13 SWOT ANALYSIS 112
14 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 113
14.1 GILEAD SCIENCES INC 113
14.1.1 COMPANY SNAPSHOT 113
14.1.2 REVENUE ANALYSIS 114
14.1.3 COMPANY SHARE ANALYSIS 114
14.1.4 PRODUCT PORTFOLIO 115
14.1.5 RECENT DEVELOPMENT 115
14.2 TERUMO CORPORATION 116
14.2.1 COMPANY SNAPSHOT 116
14.2.2 REVENUE ANALYSIS 116
14.2.3 COMPANY SHARE ANALYSIS 117
14.2.4 PRODUCT PORTFOLIO 117
14.2.5 RECENT DEVELOPMENT 117
14.3 GETINGE 118
14.3.1 COMPANY SNAPSHOT 118
14.3.2 REVENUE ANALYSIS 118
14.3.3 COMPANY SHARE ANALYSIS 119
14.3.4 PRODUCT PORTFOLIO 119
14.3.5 RECENT DEVELOPMENT 119
14.4 LIVANOVA PLC 120
14.4.1 COMPANY SNAPSHOT 120
14.4.2 REVENUE ANALYSIS 120
14.4.3 COMPANY SHARE ANALYSIS 121
14.4.4 PRODUCT PORTFOLIO 121
14.4.5 RECENT DEVELOPMENTS 121
14.5 MEDTRONIC 122
14.5.1 COMPANY SNAPSHOT 122
14.5.2 REVENUE ANALYSIS 122
14.5.3 COMPANY SHARE ANALYSIS 123
14.5.4 PRODUCT PORTFOLIO 123
14.5.5 RECENT DEVELOPMENTS 123
14.6 ARMSTRONG MEDICAL 124
14.6.1 COMPANY SNAPSHOT 124
14.6.2 PRODUCT PORTFOLIO 124
14.6.3 RECENT DEVELOPMENT 124
14.7 BESMED HEALTH BUSINESS CORP 125
14.7.1 COMPANY SNAPSHOT 125
14.7.2 PRODUCT PORTFOLIO 125
14.7.3 RECENT DEVELOPMENTS 126
14.8 DRÄGERWERK AG & CO. KGAA 127
14.8.1 COMPANY SNAPSHOT 127
14.8.2 REVENUE ANALYSIS 127
14.8.3 PRODUCT PORTFOLIO 128
14.8.4 RECENT DEVELOPMENTS 128
14.9 EUROSETS 129
14.9.1 COMPANY SNAPSHOT 129
14.9.2 PRODUCT PORTFOLIO 129
14.9.3 RECENT DEVELOPMENT 129
14.10 FISHER & PAYKEL HEALTHCARE LIMITED 130
14.10.1 COMPANY SNAPSHOT 130
14.10.2 REVENUE ANALYSIS 130
14.10.3 PRODUCT PORTFOLIO 131
14.10.4 RECENT DEVELOPMENTS 131
14.11 FRESENIUS SE & CO. KGAA 132
14.11.1 COMPANY SNAPSHOT 132
14.11.2 REVENUE ANALYSIS 132
14.11.3 PRODUCT PORTFOLIO 133
14.11.4 RECENT DEVELOPMENT 133
14.12 HAMILTON MEDICAL 134
14.12.1 COMPANY SNAPSHOT 134
14.12.2 PRODUCT PORTFOLIO 134
14.12.3 RECENT DEVELOPMENT 134
14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD 135
14.13.1 COMPANY SNAPSHOT 135
14.13.2 PRODUCT PORTFOLIO 135
14.13.3 RECENT DEVELOPMENT 135
14.14 NIPRO 136
14.14.1 COMPANY SNAPSHOT 136
14.14.2 REVENUE ANALYSIS 136
14.14.3 PRODUCT PORTFOLIO 137
14.14.4 RECENT DEVELOPMENT 137
14.15 PFIZER INC 138
14.15.1 COMPANY SNAPSHOT 138
14.15.2 REVENUE ANALYSIS 138
14.15.3 PRODUCT PORTFOLIO 139
14.15.4 RECENT DEVELOPMENT 139
14.16 RESMED 140
14.16.1 COMPANY SNAPSHOT 140
14.16.2 REVENUE ANALYSIS 140
14.16.3 PRODUCT PORTFOLIO 141
14.16.4 RECENT DEVELOPMENT 141
14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 142
14.17.1 COMPANY SNAPSHOT 142
14.17.2 PRODUCT PORTFOLIO 142
14.17.3 RECENT DEVELOPMENT 142
15 QUESTIONNAIRE 143
16 RELATED REPORTS 146